News

Public · Published

Medline Inc. Stock 12‑Month Price Target Raised to $44.62, Implies 31% Upside

Estimates from 26 analysts raised Medline Inc.'s average 12-month stock price target from $44.27 to $44.62. Based on the Nov. 3 closing price, the new target implies approximately 31% potential upside. The consensus rating remains Buy, with 23 Buys, 6 Holds and no Sells among 29 analysts.

Published:

Updated:

What happened

Estimates from 26 analysts raised Medline Inc.’s average 12-month stock price target from $44.27 to $44.62. Based on the Nov. 3 closing price, the new target implies approximately 31% potential upside. The consensus rating remains Buy, with 23 Buys, 6 Holds and no Sells among 29 analysts.

Confirmed

Global impact / market context

A higher analyst target signals that estimates of Medline’s future share value have improved, but it is not a guarantee of returns. If investors act on the implied upside, demand for the stock could rise; the unchanged Buy consensus shows broad optimism, though six analysts remain on Hold.

Analyst inference

The target is an average forecast, not a company promise or a measure of current earnings. Forecasts range from $34 to $55 per share, showing meaningful disagreement among analysts. The article gives no explanation for the revision or information about Medline’s business results.

Confirmed

What to watch

  1. The next analyst target revisions could show whether the move from $44.27 to $44.62 is followed by further increases or reversed by new estimates. Analyst inference
  2. Compare future company results with the $34-to-$55 forecast range; results that differ from analysts’ expectations could change their targets and ratings. Analyst inference
  3. The consensus remains Buy, with 23 Buys, 6 Holds and no Sells among 29 analysts; watch whether that rating mix changes in later updates. Confirmed

Evidence

  • Original source link unavailable